Winslow Capital Management LLC Trims Holdings in Stryker Co. (NYSE:SYK)

Winslow Capital Management LLC lowered its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 4.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,010,821 shares of the medical technology company's stock after selling 49,410 shares during the quarter. Stryker accounts for about 1.3% of Winslow Capital Management LLC's investment portfolio, making the stock its 27th largest position. Winslow Capital Management LLC owned approximately 0.27% of Stryker worth $363,946,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Morse Asset Management Inc lifted its holdings in shares of Stryker by 16.5% in the third quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company's stock worth $509,000 after buying an additional 200 shares in the last quarter. MML Investors Services LLC increased its holdings in shares of Stryker by 6.3% in the third quarter. MML Investors Services LLC now owns 35,392 shares of the medical technology company's stock worth $12,786,000 after purchasing an additional 2,098 shares during the last quarter. Nomura Asset Management Co. Ltd. boosted its stake in Stryker by 44.1% during the third quarter. Nomura Asset Management Co. Ltd. now owns 147,007 shares of the medical technology company's stock valued at $53,108,000 after buying an additional 44,963 shares during the last quarter. Groupama Asset Managment grew its holdings in Stryker by 30.0% during the 3rd quarter. Groupama Asset Managment now owns 1,326 shares of the medical technology company's stock valued at $479,000 after buying an additional 306 shares in the last quarter. Finally, LRI Investments LLC increased its stake in Stryker by 14.9% in the 3rd quarter. LRI Investments LLC now owns 340 shares of the medical technology company's stock worth $130,000 after acquiring an additional 44 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Citigroup reiterated a "buy" rating and set a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Barclays upped their price objective on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Stifel Nicolaus increased their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Finally, Truist Financial lifted their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $423.05.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Stock Performance

Stryker stock traded up $1.43 during midday trading on Monday, hitting $351.71. 449,529 shares of the company were exchanged, compared to its average volume of 1,355,922. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market capitalization of $134.24 billion, a PE ratio of 45.32, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The business has a fifty day simple moving average of $375.54 and a two-hundred day simple moving average of $373.63. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the firm earned $3.46 earnings per share. On average, sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.96%. Stryker's dividend payout ratio (DPR) is 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.